Brainstorm Cell Therapeutics | BCLI - Operating Expenses


Brainstorm Cell Therapeutics reported $3.09M in Operating Expenses for its fiscal quarter ending in March of 2025.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Biogen USD 1.88B 81.4M Sep/2025
Brainstorm Cell Therapeutics USD 3.09M 100K Mar/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Grifols EUR 1.77B 22.04M Sep/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Mesoblast USD 56.15M 32.57M Jun/2025